CTLA4 and hepatocellular carcinoma: The HIMALAYA trial was a three-arm study that compared the combination of tremelimumab (CTLA-4 inhibitor) with durvalumab (PD-L1 inhibitor), durvalumab monotherapy, and sorafenib in patients with unresectable HCC.